Nevertheless, bevacizumab carries risks of hypertension, impaired wound healing, and rare gastrointestinal perforation, so formal phase II trials are needed to define optimal dosing, duration, and patient selection criteria before anti-VEGF therapy can be recommended outside of experimental protocols. The gene discussed is VEGFA; the disease is hypertensive disorder.